A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

Trial Profile

A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms PROTEC
  • Sponsors Biogen
  • Most Recent Events

    • 28 Oct 2017 Results of post hoc subgroup analyses assessing the impact of dimethyl fumarate on clinical endpoints and patient related outcomes in patients enrolled in France presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results of a subgroup analysis assessing the effectiveness of delayed-release dimethyl fumarate on annualized relapse rate in newly diagnosed MS patients presented at the 69th Annual Meeting of the American Academy of Neurology
    • 08 Mar 2017 Planned End Date changed from 1 Mar 2016 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top